<DOC>
	<DOCNO>NCT02966756</DOCNO>
	<brief_summary>This Phase 2 , open-label , single-arm , multicenter study , evaluate efficacy venetoclax participant relapse refractory Chronic Lymphocytic Leukemia ( CLL ) presence 17p deletion .</brief_summary>
	<brief_title>A Study Venetoclax Subjects With Relapsed Refractory Chronic Lymphocytic Leukemia Presence 17p Deletion</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Participant must diagnosis relapsed refractory chronic lymphocytic leukemia ( CLL ) meet 2008 Modified International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) NCIWG Guidelines follow : Participant must indication treatment accord 2008 Modified IWCLL National Cancer InstituteWorking Group ( NCIWG ) Guidelines ; Participant must measurable disease ( Blymphocytosis great 5 Ã— 10^9/L enlarge lymph node ( ) ( LDi &gt; 1.5 cm baseline ) hepatomegaly splenomegaly due CLL ) ; Participant must relapse refractory CLL receive least one prior line therapy Relapsed must complete least 2 cycle one prior line therapy ; Refractory must progress least 1 cycle one prior line therapy ; Participant must 17p deletion , assessed central laboratory ( bone marrow peripheral blood ) . Participant must Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 . Participant must adequate bone marrow function , coagulation profile , renal , hepatic function , per laboratory reference range Screening Participant undergone allogeneic stem cell transplant . Participant develop Richter 's transformation confirm biopsy . Participant prolymphocytic leukemia . Participant active uncontrolled autoimmune cytopenia ( 2 week prior screen ) , include autoimmune hemolytic anemia ( AIHA ) idiopathic thrombocytopenic purpura ( ITP ) . Participant previously receive venetoclax . Participant known positive Human Immunodeficiency Virus ( HIV ) . Participant receive biologic agent antineoplastic intent within 30 day prior first dose study drug . Participant receive follow within 14 day 5 halflives ( whichever short ) prior first dose study drug , recover less Common Toxicity Criteria ( CTC ) grade 2 clinically significant adverse effect ( ) /toxicity ( ) previous therapy : Any anticancer therapy include chemotherapy , radiotherapy ; Investigational therapy , include target small molecule agent . Participant know allergy xanthine oxidase inhibitor rasburicase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsed chronic lymphocytic leukemia ( CLL )</keyword>
	<keyword>Leukemia</keyword>
	<keyword>17p deletion</keyword>
	<keyword>Refractory chronic lymphocytic leukemia ( CLL )</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>venetoclax</keyword>
</DOC>